PMID- 20238486
OWN - NLM
STAT- MEDLINE
DCOM- 20100603
LR  - 20181113
IS  - 1573-2576 (Electronic)
IS  - 0360-3997 (Linking)
VI  - 33
IP  - 2
DP  - 2010 Apr
TI  - Schisantherin A exhibits anti-inflammatory properties by down-regulating 
      NF-kappaB and MAPK signaling pathways in lipopolysaccharide-treated RAW 264.7 
      cells.
PG  - 126-36
LID - 10.1007/s10753-009-9166-7 [doi]
AB  - Schisantherin A, a dibenzocyclooctadiene lignan isolated from the fruit of 
      Schisandra sphenanthera, has been used as an antitussive, tonic, and sedative 
      agent under the name of Wuweizi in Chinese traditional medicine. In the present 
      study, we carry out a screening program to identify the anti-inflammatory 
      potentials of schisantherin A. We found that schisantherin A reduced 
      lipopolysaccharide (LPS (1 mg/L))-induced levels of TNF-alpha, IL-6, NO, and PGE2 
      (p<0.01 or p<0.05), and also reduced levels of iNOS and COX-2 in RAW 264.7 
      macrophages in a concentration-dependent manner. We further investigated signal 
      transduction mechanisms to determine how schisantherin A affects. RAW264.7 cells 
      were pretreated with 0.5, 2.5, or 25 mg/L of schisantherin A 1 h prior to 
      treatment with 1 mg/L of LPS. Thirty minutes later, cells were harvested and 
      mitogen activated protein kinases (MAPKs) activation and I kappaB alpha was 
      measured by Western blot. Alternatively, cells were fixed and nuclear 
      factor-kappaB (NF-kappaB) activation was measured using immunocytochemical 
      analysis. Signal transduction studies showed that schisantherin A significantly 
      inhibited extracellular signal-regulated kinase (ERK), p38, and c-jun 
      NH2-terminal kinase (JNK) phosphorylation protein expression. Schisantherin A 
      also inhibited p65-NF-kappaB translocation into the nucleus by I kappaB alpha 
      degradation. By using specific inhibitors of ERK, JNK and p38, we found that 
      schisantherin A may inhibit TNF-alpha mostly through ERK pathway. Therefore, 
      schisantherin A may inhibit LPS-induced production of inflammatory cytokines by 
      blocking NF-kappaB and MAPKs signaling in RAW264.7 cells.
FAU - Ci, Xinxin
AU  - Ci X
AD  - Department of Veterinary Pharmacology, College of Animal Science and Veterinary 
      Medicine, Jilin University, Changchun, Jilin, 130062, People's Republic of China.
FAU - Ren, Rong
AU  - Ren R
FAU - Xu, Kan
AU  - Xu K
FAU - Li, Hongyu
AU  - Li H
FAU - Yu, Qinlei
AU  - Yu Q
FAU - Song, Yu
AU  - Song Y
FAU - Wang, Dacheng
AU  - Wang D
FAU - Li, Rongtao
AU  - Li R
FAU - Deng, Xuming
AU  - Deng X
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Inflammation
JT  - Inflammation
JID - 7600105
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Cyclooctanes)
RN  - 0 (Dioxoles)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Interleukin-6)
RN  - 0 (Lignans)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (NF-kappa B)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Rela protein, mouse)
RN  - 0 (Transcription Factor RelA)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (lipopolysaccharide, E coli O55-B5)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 82042-38-4 (schizandrer A)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
RN  - EC 1.14.13.39 (Nos2 protein, mouse)
RN  - EC 1.14.99.- (Ptgs2 protein, mouse)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 2.7.11.10 (Chuk protein, mouse)
RN  - EC 2.7.11.10 (I-kappa B Kinase)
RN  - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
RN  - EC 2.7.11.24 (JNK Mitogen-Activated Protein Kinases)
RN  - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
RN  - K7Q1JQR04M (Dinoprostone)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Cell Line
MH  - Cell Survival/drug effects
MH  - Cyclooctanes/*pharmacology
MH  - Cyclooxygenase 2
MH  - Dinoprostone/metabolism
MH  - Dioxoles/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Extracellular Signal-Regulated MAP Kinases/antagonists & inhibitors/metabolism
MH  - I-kappa B Kinase/metabolism
MH  - Inflammation Mediators/metabolism
MH  - Interleukin-6/metabolism
MH  - JNK Mitogen-Activated Protein Kinases/antagonists & inhibitors/metabolism
MH  - Lignans/*pharmacology
MH  - Lipopolysaccharides/*pharmacology
MH  - MAP Kinase Signaling System/*drug effects
MH  - Macrophages/*drug effects/enzymology/immunology
MH  - Mice
MH  - NF-kappa B/*metabolism
MH  - Nitric Oxide/metabolism
MH  - Nitric Oxide Synthase Type II
MH  - Phosphorylation
MH  - Protein Kinase Inhibitors/*pharmacology
MH  - Transcription Factor RelA/metabolism
MH  - Tumor Necrosis Factor-alpha/metabolism
MH  - p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors/metabolism
EDAT- 2010/03/20 06:00
MHDA- 2010/06/04 06:00
CRDT- 2010/03/19 06:00
PHST- 2010/03/19 06:00 [entrez]
PHST- 2010/03/20 06:00 [pubmed]
PHST- 2010/06/04 06:00 [medline]
AID - 10.1007/s10753-009-9166-7 [doi]
PST - ppublish
SO  - Inflammation. 2010 Apr;33(2):126-36. doi: 10.1007/s10753-009-9166-7.